CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

As expected, the Q3 earnings season has been sluggish, with no major shocks or disappointments. Corporates have reported a single digit profitability in Q3FY25, said Shantanu Bhargava.

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...